Please try another search
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors, used for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Name | Age | Since | Title |
---|---|---|---|
Robert N. Wilson | 83 | 2020 | Independent Chairman of the Board |
A. Rachel Leheny | 61 | 2019 | CEO & Director |
Eric W. Roberts | 60 | 2020 | Chief Business Officer & Vice Chairman of the Board |
Frederic Guerard | 51 | - | Independent Director |
Allan J. Lee Shaw | 60 | 2021 | Independent Director |
Eric H. Bjerkholt | 64 | - | Independent Director |
Fred A. Middleton | 75 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review